Prem Watsa
Fairfax Financial Holdings
Prem Watsa CUBIST PHARMACEUTICALS LLC stake
total: 291
Fairfax Financial Holdings CBST trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2015 Q1
According to 2026 Q2 report, Prem Watsa doesn't hold any CUBIST PHARMACEUTICALS LLC (CBST) shares. To date, the estimated cost basis is nearly $100.69 for "buy" trades and estimated average "sell" price is $100.69. Fairfax Financial Holdings first purchased CBST in 2014 Q4, initially acquiring 20,200 shares. Since the initial investment in CUBIST PHARMACEUTICALS LLC (CBST), Fairfax Financial Holdings has made 1 more transaction.
When did Prem Watsa sell CUBIST PHARMACEUTICALS LLC (CBST)?
Prem Watsa sold off the entire CUBIST PHARMACEUTICALS LLC (CBST) position in 2015 Q1.
When did Prem Watsa buy CUBIST PHARMACEUTICALS LLC (CBST)?
Prem Watsa first invested in CUBIST PHARMACEUTICALS LLC (CBST) in 2014 Q4 at the reported quarter-end price of $100.69 per share.
What's the cost basis of Fairfax Financial Holdings's CBST stake?
The estimated cost basis for CUBIST PHARMACEUTICALS LLC (CBST) stake is around $100.69 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $100.69
- Weighted AVG sell price:
- $100.69
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.